Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
Measurable residual disease
Multiparametric flow cytometry
Next-generation sequencing
Precursor B-lymphoblastic leukemia
Sensitivity
Journal
Journal of hematopathology
ISSN: 1865-5785
Titre abrégé: J Hematop
Pays: Germany
ID NLM: 101491976
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
10
02
2023
accepted:
03
04
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
4
1
2024
Statut:
ppublish
Résumé
Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from electronic medical records and data was reviewed. Included in this study were 74 bone marrow samples collected from 31 B-ALL patients at our institution between January 2021 and March 2022. COG MFC and ClonoSEQ results were concordant in 59/74 samples (80%) with positive concordant results in 12 samples (16%) and negative concordant results in 47 samples (64%). Discordant results were seen in 15/74 samples (20%), with 14 samples (19%) showing ClonoSEQ + /MFC- results and only 1 sample (1%) showing MFC + /ClonoSEQ- result. ClonoSEQ + /MFC- cases had MRD values ranging from 1 to 1400 cells/million nucleated cells with 86% of cases showing MRD values of < 100 cells/million nucleated cells. Newly identified dominant sequences were detected using ClonoSEQ in 2/31 patients (6%) during follow-up. All 14 bone marrow samples from 8 patients, who had gone through blinatumomab immunotherapy, were MRD negative by MFC, but 3 cases were MRD positive by ClonoSEQ. Our results show strong correlation between COG MFC and ClonoSEQ (r = 0.96), and both methods are complementary. Clonal evolution may occur, and blinatumomab immunotherapy may impact MFC B-ALL MRD evaluation.
Identifiants
pubmed: 38175444
doi: 10.1007/s12308-023-00544-9
pii: 10.1007/s12308-023-00544-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-94Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Buckley S, Appelbaum F, Walter R (2013) Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 48(5):630–641
doi: 10.1038/bmt.2012.139
pubmed: 22825427
Correia R, Bento L, de Sousa F et al (2021) How I investigate minimal residual disease in acute lymphoblastic leukemia. Int J Lab Hematol 43(3):354–363. https://doi.org/10.1111/ijlh.13463
doi: 10.1111/ijlh.13463
pubmed: 33423385
Short N, Jabbour E (2017) Minimal residual disease in acute lymphoblastic leukemia: how to recognize and treat It. Curr Oncol Rep 19(1):6
doi: 10.1007/s11912-017-0565-x
pubmed: 28205134
Borowitz M, Wood B, Devidas M et al (2015) Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood 126(8):964–971
doi: 10.1182/blood-2015-03-633685
pubmed: 26124497
pmcid: 4543229
Topp M, Kufer P, Gökbuget N et al (2011) Targeted therapy with the T-cell–engaging antibody Blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29(18):2493–2498. https://doi.org/10.1200/JCO.2010.32.7270
doi: 10.1200/JCO.2010.32.7270
pubmed: 21576633
Lovisa F, Zecca M, Rossi B et al (2018) Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol 180(5):680–693
doi: 10.1111/bjh.15086
pubmed: 29359790
Kruse A, Abdel-Azim N, Kim H et al (2020) Minimal residual disease detection in acute lymphoblastic leukemia. Int J Mol Sci 21(3):1054
doi: 10.3390/ijms21031054
pubmed: 32033444
pmcid: 7037356
Sánchez R, Ayala R, Martínez-López J (2019) Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies. Int J Mol Sci 20(11):2832. https://doi.org/10.3390/ijms20112832
doi: 10.3390/ijms20112832
pubmed: 31185671
pmcid: 6600313
Monter A, Nomdedéu J (2019) ClonoSEQ assay for the detection of lymphoid malignancies. Expert Rev Mol Diag 19(7):571–578. https://doi.org/10.1080/14737159.2019.1627877
doi: 10.1080/14737159.2019.1627877
Ching T, Duncan M, Newman-Eerkes T et al (2020) Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer 20(1):612. https://doi.org/10.1186/s12885-020-07077-9
doi: 10.1186/s12885-020-07077-9
pubmed: 32605647
pmcid: 7325652
Tierens A, Stockley T, Campbell C et al (2021) Consensus recommendations for MRD testing in adult B-cell acute lymphoblastic leukemia in Ontario. Curr Oncol 28(2):376–1387. https://doi.org/10.3390/curroncol28020131
doi: 10.3390/curroncol28020131
Cheng S, Inghirami G, Cheng S et al (2018) Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. J Hematol Oncol 11(1):105. https://doi.org/10.1186/s13045-018-0652-y
doi: 10.1186/s13045-018-0652-y
pubmed: 30134947
pmcid: 6103872
Liu Z, Li Y, Shi C (2021) Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy. Int J Hematol 113(3):337–343. https://doi.org/10.1007/s12185-021-03085-y
doi: 10.1007/s12185-021-03085-y
pubmed: 33502735
Torra O, Othus M, Williamson D et al (2017) Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant 23(4):691–696
doi: 10.1016/j.bbmt.2016.12.639
pmcid: 5465962
Theunissen P, Mejstrikova E, Sedek L et al (2017) EuroFlow Consortium. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129(3):347–357
doi: 10.1182/blood-2016-07-726307
pubmed: 27903527
pmcid: 5291958
Cherian S, Soma L (2021) How I diagnose minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma by flow cytometry. Am J Clin Pathol 155(1):38–54. https://doi.org/10.1093/AJCP/AQAA242
doi: 10.1093/AJCP/AQAA242
pubmed: 33236071
Chernysheva O, Grivtsova L, Popa A, et al. (2020) B-cell precursors: immunophenotypic features in the detection of minimal residual disease in acute leukemia, in: M Aribi, Normal and malignant B-cell, Intechopen, https://doi.org/10.5772/intechopen.78445 , https://www.intechopen.com/books/8316 . Accessed 2/1/2023
Nagant C, Casula D, Janssens A et al (2018) Easy discrimination of hematogones from lymphoblasts in B cell-progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio. Int J Lab Hematol 40(6):734–739
doi: 10.1111/ijlh.12912
pubmed: 30113764
Mikhailova E, Semchenkova A, Illarionova O et al (2021) Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease. Br J Haematol 193(3):602–612. https://doi.org/10.1111/bjh.17382
doi: 10.1111/bjh.17382
pubmed: 33715150
Hansen M, Cedile O, Larsen T et al (2021) Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements—how low can you go? Exp Hematol 98:14–24. https://doi.org/10.1016/j.exphem.2021.03.005
doi: 10.1016/j.exphem.2021.03.005
pubmed: 33823225
Medina A, Puig N, Flores-Montero J et al (2020) Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J 10(10):108. https://doi.org/10.1038/s41408-020-00377-0
doi: 10.1038/s41408-020-00377-0
pubmed: 33127891
pmcid: 7603393
Thompson P, Srivastava J, Peterson C et al (2019) Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134(22):1951–1959
doi: 10.1182/blood.2019001077
pubmed: 31537528
pmcid: 6887113
Wood B, Wu D, Crossley B et al (2018) Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 131(12):1350–1359
doi: 10.1182/blood-2017-09-806521
pubmed: 29284596
pmcid: 5865233
Gaipa G, Cazzaniga G, Valsecchi M et al (2012) Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 97(10):1582–1593
doi: 10.3324/haematol.2011.060426
pubmed: 22581001
pmcid: 3487561